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Background: The multidrug resistance (MDR) 1 gene encodes a 170-kDa membrane transporter called P-glycoprotein,
which plays an important role in protecting cells against lipophilic xenobiotics by the way of an ATP-dependent
cellular efflux mechanism. Three polymorphisms of MDR1, 3435C > T located in exon 26, 1236C > T in exon 12 and
2677G > T/A in exon 21 were the most extensively studied and were identified functionally important and ethnically
diverse mapping to the gene region. Considering the potential influence of altering MDR1 activity, it is plausible that
MDR1 polymorphisms might play a role in the development of cancer. Although the effects of MDR1 polymorphisms
on susceptibility to human cancer have been investigated in many studies, the results still remain conflicting.
Methods: To resolve these conflicts, we performed a quantitative synthesis of the association between these
three polymorphisms and cancer risk, including 52 studies (15789 cases and 20274 controls) for 3435C > T
polymorphism, 10 studies (2101 cases and 2842 controls) for 1236C > T polymorphism and 18 studies (3585 cases
and 4351 controls) for 2677G > T/A polymorphism.
Results: The stratified analyses for 3435C > T polymorphism, individuals with T-allele in 3435C > T had significantly
higher ALL risks (TT versus CC: OR =1.286, 95% CI =1.123-1.474); significantly elevated risks were observed among
Caucasian populations (TT versus CC: OR =1.276, 95% CI =1.112-1.464). When restricting the analysis to the source of
controls, we found that HB (hospital-based) genetic models had higher risks (TT versus CC: OR =1.307, 95% CI =1.046-
1.632), as well as in PB (population-based) genetic models (TT versus CC: OR =1.294, 95% CI =1.079-1.55).
The T/A-allele frequency of 2677G > T/A polymorphism was associated with higher risk of cancer (TT + TA + AA
vs. GG: OR =1.348, 95% CI =1.031-1.762), significantly elevated risks were observed among Asian populations (TT + TA +
AA vs. GG: OR =1.642, 95% CI =1.340-2.012), and elevated risks could be associated with PB models (TT + TA + AA vs.
GG: OR =1.641, 95% CI =1.018-2.646).
Conclusions: Our meta-analysis suggested that 3435C > T polymorphism and 2677G > T/A polymorphism were
associated with cancer risk when all studies were pooled together, while 1236C > T polymorphism not.
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The human multidrug resistance 1 (MDR1 or ABCB1)
gene encodes a 170-kDa membrane transport protein
called P-glycoprotein. For minimizing the exposure of
potential toxic compounds to the cellular homeostasis,
P-glycoprotein is expressed primarily in regions that act
as epithelial barriers or perform excretory functions, in-
cluding blood-tissue barrier, the gastrointestinal tract,
liver and kidney. Therefore, P-glycoprotein can play the
role of sweeper by extruding several exogenous and en-
dogenous substances, using ATP-dependent efflux pump
[1-4]. The alteration of the cellular defense mechanism
mediated by P-gp has been speculated to be closely asso-
ciated with the development of various cancers including
hepatocarcinoma, colorectal carcinoma, acute lympho-
blastic leukemia and gall bladder tumors [5-8]. These
suggest that MDR1 may play an important role in the
elimination of carcinogens, and the mutation of MDR1
may lead to human malignancies [5]. Several studies try
to prove the causal function of P-gp in tumorigenesis by
animal experiments. One study by Mochida Y et al. sug-
gested that the absence of the P-gp role suppressed the
development of intestinal neoplasia in Apc (Min/+) mice,
and a P-gp inhibitor was found to suppress tumorigenesis
in rats subsequently [9,10]. While Schinkel et al.
conducted a study comparing normal MDR1a (+/+) mice
(MDR1a is the mouse equivalent to the human MDR1
gene) to constructed MDR1a (−/−) disrupted mice to find
that the MDR1a (−/−)mice resulted in cumulative toxicity
of the pesticide, ivermectin due to decreased extrusion of
these compounds [11]. Considering these data, we can
infer that genetical absence of Pg-p expression may result
in more exposure to environmental xenobiotics so that in-
creased opportunity linked to the risk of malignancy was
obtained. However, the causal relationship betweenMDR1
and the tumorigenesis has not been fully elucidated yet.
Recently, at least 50 single-nucleotide polymorphisms
have been reported within MDR1 gene locus [12,13].
Among the systematic screens of this gene, Hoffmeyer
et al. reported significant role that a synonymous SNP
played at position 3435 located in exon 26 in the P-
glycoprotein function [14]. Recent studies have found that
C3435T was in linkage disequilibrium with two other
common SNPs, the synonymous C1236T (exon 12) and
nonsynonymous triallelic G2677T/A (exon 21) [15-17].
Considering the potential influence of these SNPs,
many molecular epidemiological studies were conducted
to investigate the association between these SNPs and
cancer risk in humans. However, the results from differ-
ent studies are to some extent divergent, but neverthe-
less intriguing, which may be owing to limitations in
individual studies. To clarify this issue, we performed a
meta-analysis with subgroup analysis from all eligible stud-
ies focusing on 3435C > T, 1236C > T and 2677G > T/A,to obtain a more precise estimation of the relationship
between polymorphisms and cancer risk.
Material and methods
Identification and eligibility of relevant studies
All case–control studies on the association between
MDR1 polymorphisms and cancer risk published up to
November 30, 2012 were identified through comprehen-
sive searches using the PubMed and Medline database,
ScienceDirect database, Springerlink database, Wiley
Online Library, BioMed Central, Nature Series, Science
Online, Cell Press Journals, CNKI, WanFang database
with the following terms and keywords: “MDR1,”
“ABCB1,” “single-nucleotide polymorphism,” and in com-
bination with “leukemia,” “cancer,” “tumor” and “carcin-
oma.” The search was limited to human studies. In
addition, we have especially reviewed the references cited
in checked articles and identified some additional articles
missed by the searching.
Inclusion criteria
The following criteria were used for the study selection:
(1) a case–control study evaluating at least one of these
three polymorphisms (3435C > T, 1236C > T and 2677G >
T/A) and cancer risk; (2) studies with full-text articles;
(3) no overlapping data. and (4) sufficient data for esti-
mating an odds ratio (OR) with 95% confidence interval
(95% CI).
Data extraction
Information was carefully extracted from all the eligible
publications. The following data were collected from each
study: first author’s name, publication date, country, ethni-
city, cancer type, source of controls (population-based
[PB] or hospital-based [HB] controls), genotyping method,
total numbers of cases and controls and number of cases
and controls for each MDR1 polymorphism. Meanwhile,
different case–control groups in one study were consid-
ered as independent studies. For each study, we did not
define a minimum number of patients for inclusion in our
meta-analysis.
Statistical methods
The strength of association between MDR1 polymor-
phisms and cancer risk was measured by ORs with 95%
CIs. The risks (ORs) of cancer associated with the three
polymorphisms were estimated for each study. In our
study, the C- allele, C-allele and G-allele were consid-
ered the reference genotypes, respectively in 3435C > T,
1236C > T and 2677G > T/A. The pooled ORs were
performed for co-dominant model (TT vs. CC and TC
vs. CC, TT + TA + AA vs. GG and GT + GA vs. GG),
dominant model (TC + TT vs. CC, TT + TA + AA +
GT + GA vs. GG) and recessive model (TT vs. TC + CC,
Wang et al. Cancer Cell International 2013, 13:46 Page 3 of 13
http://www.cancerci.com/content/13/1/46TT + TA + AA vs. GT + GA + AA), respectively. Het-
erogeneity assumption was checked by a χ2-based Q-
test. A p-value of >0.05 for the Q-test indicated a lack
of heterogeneity among studies, so that the pooled OR
estimate of each study was calculated by the fixed-
effects model (the Mantel–Haenszel method). Other-
wise, the random-effects model (the DerSimonian and
Laird method) was used. Heterogeneity was quantified
with the I2 metric, which is independent of the number
of studies in the meta-analysis (I2 < 25%: no heterogeneity;
I2 = 25–50%: moderate heterogeneity; I2 = 50–75%: large
heterogeneity, I2 > 75%: extreme heterogeneity). Subgroup
analyses were performed by cancer type (if one cancer
type contained fewer than three individual studies, it was
combined into an “other cancers” group), ethnicity and
source of controls. Before analysis for each study, we ex-
amined whether the genotype distribution of controls was
consistent with Hardy– Weinberg equilibrium using the
χ2 test. We performed One-way sensitivity analysis by de-
leting a single study in the meta-analysis each time to re-
flect the influence of the individual data set to the pooled
OR to assess the stability of the results. An estimate of po-
tential publication bias was carried out by the funnel plot,
in which the standard error of log (OR) of each study was
plotted against its log (OR). An asymmetric plot suggests
a possible publication bias. Funnel plot asymmetry was
assessed by the method of Egger’s linear regression test, a
linear regression approach to measure funnel plot asym-
metry on the natural logarithm scale of the OR. The sig-
nificance of the intercept was determined by the t-test
suggested by Egger (p < 0.05 was considered a significant
publication bias). All of the statistical tests used in our
meta-analysis were performed by SPSS version 13.0 and
STATA version 11.0 (Stata, College Station, TX).
Results
Eligible studies and meta-analysis databases
A total of 48 publications with 52 case–control studies
exploring the association between MDR1 3435C > T,
1236C > T and 2677G > T/A polymorphisms and cancer
risk were found [2,5,18-62]. Hence, as summarized in
Table 1, 52 studies (15789 cases and 20274 controls) for
3435C > T polymorphism, 10 studies (2101 cases and
2842 controls) for 1236C > T polymorphism and 18
studies (3585 cases and 4351 controls) for 2677G > T/A
polymorphism were selected in the meta-analysis, of
which one publications had three independent studies
and were considered separately. As summarized in
Table 1, there were 25 hospital-based studies and 26
population-based studies. There were 8 acute lympho-
blastic leukemia (ALL) studies, 14 colorectal cancer
studies, 9 breast cancer studies, 4 gastric cancer studies,
3 renal cell cancer studies, 2 acute myelocytic leukemia
(AML) studies, 2 lung cancer study, 2 B-cell chroniclymphocytic leukemia (CLL) studies, one endometrial
cancer study, one esophageal squamous cell carcinoma
study, one glioma study, one upper aerodigestive tract
(UADT) cancers study, one multiple myeloma study,
one leukemia study, one plasma cell myeloma study and
one study with Hodgkin’s lymphoma (HL). Thirty-three
studies were conducted in Europeans, seventeen studies
were conducted in Asians. Two of the remained studies
were conducted in Americans, and the other was in
Mexicans. These studies indicate that the distribution of
genotypes in controls was consistent with Hardy–Weinberg
equilibrium. And the subjects of controls were matched
for age and gender. Most of the cases were confirmed
histologically or pathologically.
Quantitative synthesis
There was a wide variation in the T-allele and T/A-allele
frequency of 3435C > T, 1236C > T and 2677G > T/A
polymorphism between the two major ethnicities. For
Asians, the T- allele frequency of 3435C > T was 25.52%
(95% CI =23.84–27.21%), which was significantly higher
than that in Caucasians (24.28%, 95% CI = 20.54–28.03%,
p < 0.001). There was no statistical difference for the T-
allele frequency of 1236C > T between Asians (24.28%,
95% CI = 11.37–26.56%) and Caucasians (36.11%, 95%
CI = 27.74–44.47%, p =0.633). And for Asians (23.47%,
95% CI = 19.78–25.96%) whose T/A-allele frequency of
2677G > T/A polymorphism was not equivalent as
Caucasians (22.87%, 95% CI = 11.12–35.82%, p =0.633).
Tables 2 summarizes the main results of the meta-
analysis for MDR1 3435C > T polymorphisms. Overall,
we found that individuals with T-allele in 3435C > T had
a higher risk of cancer (co-dominant model TT versus
CC: OR =1.286, 95% CI =1.123–1.474; CT versus CC:
OR = 1.126, 95% CI = 1.020–1.244; dominant model TT +
CT versus CC: OR = 1.176, 95% CI = 1.068–1.295; re-
cessive model TT versus CT + CC: OR =1.191, 95%
CI =1.065–1.333). In the subgroup analysis by cancer type,
the results indicated that individuals with T-allele in
3435C > T had significantly higher ALL risks (TT versus
CC: OR =1.890, 95% CI =1.177–3.037), otherwise no sig-
nificant association was found between higher CRC risks
and T-allele in 3435C > T, neither was between breast
cancer and T-allele in 3435C > T. When stratified by eth-
nicity, significantly elevated risks were observed among
Caucasian populations(co-dominant model TT versus CC:
OR =1.276, 95% CI =1.112–1.464; CT versus CC: OR =
1.172, 95% CI = 1.047–1.313; dominant model TT + CT
versus CC: OR = 1.212, 95% CI = 1.083–1.357), whereas
significantly elevated risks were not observed among
Asian populations (co-dominant model TT versus CC:
OR =1.314, 95% CI =0.894–1.933). When restricting the
analysis to the source of controls, we found that HB gen-
etic models had higher risks (TT versus CC: OR =1.307,
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PCR-R P 48 100 0.17;0.24;0.04 0.60;0.21;0.07
19 Zhi-zhuo Du 2010 Suzhou, China ALL Asian C3435T,
C1236T,
G2677T/A
HB Age, gender SNP- t 176 170 0.30;0.38;0.27 0.00;0.28;0.23









PCR-S P 294 369 0.25;0.21;0.18 0.30;0.13;0.18
3 Hiroyoshi Hattori 2007 Japan ALL Asian C3435T HB Age, gender Taqm n 622 96 0.18 0.3
20 Jamroziak K 2004 Poland ALL Caucasian C3435T PB Age, gender, PCR-R P 113 175 0.24 0
21 Evelia Leal-Ugarte 2008 Mexico ALL C3435T PB Gender PCR-R P 107 111 0.28 0.02




PCR-R P 378 189 0.29;0.28 0.07;0.13




PB Age, Gender, TaqM n 359 765 0.33 0.47
24 Daniele Campa 2012 Czech Republic colorectal
cancer
Caucasian C3435T HB Age, Gender, Taqm n 699 622 0.29 0.79




Caucasian C3435T HB Age, Gender,
county of
residence
Taqm n 1809 1853 0.28 0.91




Caucasian C3435T PB Age, Gender, Taqm n 2169 1634 0.29 0.62





HB Age, Gender, TaqM n 38 355 0.30;0.18;0.19 0.66;0.33;0.24
26 Nizar M Mhaidat 2011 Jordan HL Asian C3435T HB Age PCR-R P 130 120 0.35 0.11
27 Sun-Young Bae 2006 Korea colorectal
cancer
Asian C3435T HB Age, Gender, PCR-R P 111 93 0.16 0.01
28 Azam Khedri 2011 Iran colorectal
cancer
Caucasian C3435T HB Age, Gender, PCR-R P 118 137 0.35 0.56
29 Mateusz Kurzawski 2005 Poland colorectal
cancer
Caucasian C3435T HB Age, Gender, PCR-R P 184 188 0.29 0.27






































Table 1 Characteristics of studies included in the meta-analysis (Continued)






HB Age, Gender, TaqMan 47 154 0.17;0.39;0.34 0.66;0.34;0.64
31 Bo-In Lee 2006 Korea colorectal
cancer
Asian C3435T HB Age, Gender, PCR-RFLP 64 64 0.13 0.15







PCR-RFLP 285 275 0.26;0.20 0.35;0.42












HB Age, Gender, RT-PCR 146 160 0.25;0.21 0.73;0.32
35 J Sainz 2011 South Germany colorectal
cancer
Caucasian C3435T PB Age, Gender, PCR 1765 1784 0.27 0.6
36 Cizmarikova 2010 Eastern Slovakia breast cancer Caucasian C3435T PB Age, Gender, PCR-RFLP 221 113 0.27 0.6
37 M. Taheri 2010 Iran breast cancer Caucasian C3435T HB Age, Gender, PCR-RFLP 54 50 0.26 0.61
38 Tatari F 2009 North east of
Iran
breast cancer Caucasian C3435T HB Gender, PCR 106 77 0.29 0.59
39 Joseph George 2009 India breast cancer Asian C3435T HB Gender, PCR 86 68 0.15 0.7
40 Henriquez-
Hernandez
2009 Spain breast cancer Caucasian C3435T HB Gender, PCR-RFLP 135 301 0.19 0.66
41 Nordgard 2007 Norway breast cancer Caucasian C3435T,
C1236T,
G2677T/A
N.A. Age, Gender, PCR-RFLP 109 93 0.13;0.26;0.26 0.27;0.16;0.03
42 Sebahat Turgut 2007 Turkey breast cancer Caucasian C3435T PB Gender, PCR-RFLP 57 50 0.24 0.62
43 Wu H 2012 China breast cancer Asian C3435T,
C1236T,
G2677T/A
PB Age, Gender, PCR-RFLP 1173 1244 0.17;0.41;0.17 0.01;0.04;0.94
44 Z Sabahi 2010 Iran Gastric cancer Caucasian C3435T PB Age, Gender, PCR 48 131 0.3 0.58
45 Mitsushige
Sugimoto
2008 Japan Gastric cancer Asian C3435T HB Age, Gender, PCR-RFLP 150 168 0.17 0.68
46 Tomomitsu Tahara 2006 Japan Gastric cancer Asian C3435T HB Age, Gender, PCR-RFLP 157 104 0.21 0.64
47 P.M. MROZIKIEWICZ 2007 Poland endometrial
cancer
Caucasian C3435T PB Age, Gender, PCR 198 488 0.26 0.61
48 Federica Gemignani 2007 six Central and
Eastern European
countries
lung cancer Caucasian C3435T,
G2677T/A
HB Age, Gender, TaqMan 299 317 0.24;0.21 0.62;0.01
49 S Haenisch 2007 Germany renal cell cancer Caucasian C3435T,
G2677T/A















Table 1 Characteristics of studies included in the meta-analysis (Continued)
50 Krzysztof Jamroziak 2006 Poland AML Caucasian C3435T PB Age, Gender, PCR-RFLP 180 180 0.23 0.64
51 Katie L. Miller 2005 USA Glioma Caucasian C3435T PB Age, Gender, PCR-RFLP 382 464 0.25 0.61
52 Krzysztof Jamroziak 2006 Poland B-cell CLL Caucasian C3435T PB Age, Gender, PCR-RFLP 110 201 0.2 0.65
53 Michael
Siegsmund
2002 Germany clear cell renal
cell carcinoma
(CCRCC)
Caucasian C3435T PB Age, Gender, PCR-RFLP 179 150 0.29 0.59
53 Michael
Siegsmund
2002 Germany non-CCRCC Caucasian C3435T PB Age, Gender, PCR-RFLP 83 150 0.3 0.58
54 Guillermo
Gervasini
2006 Spain lung cancer Caucasian C3435T,
G2677T/A
PB Age, Gender, TaqMan 96 86 0.26;0.31 0.61;0,。60




Asian C3435T HB Age, Gender, PCR-RFLP 219 210 0.35 0.55





PB Age, Gender, PCR-RFLP 111 96 0.19;0.15;0.18 0.66;0.01;0.55
57 V Rocha 2008 France leukemia Caucasian C3435T PB Age, Gender, PCR-RFLP 107 107 0.2 0.65
58 STEPHEN DRAIN 2009 UK plasma cell
myeloma
Caucasian C3435T PB Age, Gender, PCR-RFLP 92 92 0.28 0.6
59 G. Penna 2010 Italy B-cell CLL Caucasian C3435T,
G2677T
PB Age, Gender, PCR-RFLP 125 125 0.25;0.30 0.62;0.00
60 The MARIE-GENICA
Consortium
2010 Germany breast cancer Caucasian C3435T PB Age, Gender, MALDI-
TOFMS
3148 5486 0.22 0.64
61 HYUN CHANG 2009 Korea Gastric cancer Asian C3435T,
G2677T/A
PB Age, Gender, PCR 43 118 0.34;0.23 0.56;0.21
62 D Nageswara Rao 2010 India AML Asian C3435T PB Age, Gender, PCR-RFLP 143 249 0.28 0.6
62 D Nageswara Rao 2010 India ALL Asian C3435T PB Age, Gender, PCR-RFLP 147 249 0.37 0.54















Table 2 Stratified analysis of the MDR1 3435C > T polymorphism on cancer risk
Genetic model Homozygote Heterozygote Dominant model Recessive model
Sample size
(case/control)
OR (95% CI) ph I
2 (%) OR (95% CI) ph I
2 (%) OR (95% CI) ph I
2 (%) OR (95% CI) ph I
2 (%)
TT vs. CC TC vs. CC TT + TC vs. CC TT vs. TC + CC




8(1381/1459) 1.890(1.177-3.037) 0.000 77.60% 0.981(0.683-1.410) 0.001 70.10% 1.240(1.046-1.470) 0.153 34.50% 1.829(1.095-3.054) 0.000 87.30%
Colorectal cancer 14(6362/7274) 1.047(0.875-1.254) 0.006 55.90% 1.053(0.906-1.224) 0.013 51.80% 1.054(0.907-1.225) 0.005 56.60% 1.014(0.939-1.094) 0.037 44.50%
breast cancer 9(5073/7498) 1.187(0.869-1.621) 0.001 69.30% 0.992(0.912-1.079) 0.190 28.70% 1.098(0.906-1.331) 0.024 54.80% 1.134(0.905-1.420) 0.017 57.10%
Ethnicity
Caucasian 33(12146/15989) 1.276(1.112-1.464) 0.000 60.40% 1.172(1.047-1.313) 0.000 54.9% 1.212 (1.083-1.357) 0.000 60.2% 1.062 (1.005-1.122) 0.001 47.7%
Asian 17(2966/3418) 1.314(0.894-1.933) 0.000 80.4% 1.072(0.837-1.374) 0.000 67.4% 1.153(0.915-1.453) 0.000 67.9% 1.236(0.867-1.763) 0.000 84.4%
Source of control
HB 25(5553/6173) 1.307(1.046-1.632) 0.000 69.10% 1.090(0.913-1.302) 0.000 64.60% 1.170(1.009-1.357) 0.001 54.90% 1.221(0.995-1.498) 0.000 76.80%
PB 26(10143/13992) 1.294(1.079-1.552) 0.000 73.90% 1.150(1.019-1.299) 0.001 53.20% 1.479(1.267-1.726) 0.000 77.60% 1.183(1.033-1.355) 0.000 69.60%
TT vs. CC TC vs. CC TT + TC vs. CC TT vs. TC + CC
C1236T 10(2101/2842) 1.325(0.824-2.133) 0.000 77.10% 1.133(0.817-1.573) 0.005 62.20% 1.173(0.825-1.668) 0.000 70.60% 1.191(0.840-1.690) 0.000 77.80%
TT + AA + TA vs.
GG
TG + TA vs. GG TT + AA + TA +
TG + TA vs. GG
TT + AA + TA vs.
TG + TA + GG
G2677T/A 18(3585/4351) 1.348(1.031-1.762) 0.000 68.70% 1.096(0.986-1.218) 0.136 27.50% 1.161(1.051-1.281) 0.019 45.50% 1.278(1.022-1.597) 0.000 68.00%
Ethnicity
Caucasian 11(1728/1950) 1.363(0.921-2.016) 0.000 73.60% 1.081(0.852-1.373) 0.029 50.10% 1.149(0.899-1.467) 0.007 58.80% 1.271(0.906-1.782) 0.000 74.60%
Asian 6(1583/2040) 1.642(1.340-2.012) 0.142 39.50% 1.153(0.989-1.344) 0.804 0.00% 1.273(1.101-1.471) 0.643 0.00% 1.481(1.244-1.763) 0.192 32.50%
Source of control
HB 10(1489/2220) 1.036(0.847-1.267) 0.045 47.80% 1.025(0.874-1.202) 0.072 43.00% 1.032(0.888-1.198) 0.077 42.10% 1.028(0.867-1.219) 0.137 33.90%
PB 7(2005/2022) 1.641(1.018-2.646) 0.000 77.20% 1.164(1.008-1.345) 0.418 0.70% 1.284(1.122-1.470) 0.099 43.80% 1.537(0.998-2.366) 0.000 80.10%
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http://www.cancerci.com/content/13/1/4695% CI =1.046–1.632; dominant model: OR =1.170, 95%
CI =1.009–1.357), and association was detected in PB
genetic models also (TT versus CC: OR =1.294, 95%
CI =1.079–1.552; CT versus CC: OR = 1.150, 95% CI =
1.019–1.299; dominant model TT + CT versus CC:
OR = 1.459, 95% CI = 1.246–1.709; recessive model TT
versus CT + CC: OR =1.183, 95% CI =1.033–1.355)
(Figure 1).
We also found that T/A-allele frequency of 2677G >
T/A polymorphism was associated with higher risk of
bearing cancer (2677G > T/A: TT + TA + AA vs. GG:
OR =1.348, 95% CI =1.031–1.762; dominant model:
OR = 1.161, 95% CI = 1.051–1.281; recessive model: OR =
1.278, 95% CI =1.022–1.597). In the subgroup analysis by
ethnicity, significantly elevated risks were observed among
Asian populations (co-dominant model TT + TA + AA vs.
GG: OR =1.642, 95% CI =1.340–2.012; dominant model:
OR = 1.273, 95% CI = 1.101–1.471; recessive model: OR =
1.481, 95% CI = 1.244–1.763), however no significantly el-
evated risks were observed among Caucasian populations.NOTE: Weights are from random effects analysis





































Figure 1 Forest plot of cancer risk associated with the MDR1 3435C >
horizontal lines correspond to the study-specific OR and 95% CI. The area o
variance). The diamonds represent the pooled OR and 95% CI.When stratified by the source of controls, we couldn’t
find association between HB genetic models and
higher cancer risks, but elevated risks could be associ-
ated with PB models (TT + TA + AA vs. GG: OR =1.641,
95% CI =1.018–2.646; GA + GT vs. GG: OR =1.164, 95%
CI =1.008–1.345; dominant model: OR = 1.284, 95%
CI =1.122–1.470).
The combined result based on all studies showed that
there was no statistically significant link between cancer
risk and 1236C > T (1236C > T: TT vs. CC: OR =1.325, 95%
CI =0.824–2.133; CT vs. CC: OR= 1.133, 95% CI = 0.817–
1.573; dominant model: OR = 1.173, 95% CI = 0.825–
1.688; recessive model: OR = 1.191, 95% CI =0.840–1.690)
(Table 2).
Heterogeneity and sensitivity analyses
For 3435C > T polymorphism, there was substantial hetero-
geneity among these studies for homozygote comparison
(TT vs. CC: p heterogeneity = 0.000), and recessive model








































































T polymorphism (TT vs. CC, random effects). The squares and
f the squares reflects the study-specific weight (inverse of the
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http://www.cancerci.com/content/13/1/46Then, we assessed the source of heterogeneity for homozy-
gote comparison (TT vs. CC) by ethnicity, cancer type and
source of controls. We found that cancer type (χ2 =
18.51, df = 2 and p < 0.001), ethnicity (χ2 = 9.58, df = 1
and p = 0.002) and the source of controls (χ2 = 4.42, df = 1
and p = 0.036) all contributed to substantial heterogeneity.
Although the sample size for cases and controls in 52
studies ranged from 38 to 5,486, the corresponding pooled
ORs were not qualitatively altered with or without the
study of small sample. Similarly, no other single study
influenced the pooled OR materially as indicated by sensi-
tivity analysis.
And for 2677G > T/A polymorphism, there was also
heterogeneity for homozygote comparison (TT + TA +
AA vs. GG: p heterogeneity = 0.000), recessive model
comparison (p heterogeneity < 0.001). The heterogeneity
we decided to analyze was homozygote comparison (TT +
TA + AA vs. GG). Due to cancer type (χ2 = 20.14, df = 7
and p = 0.005) and the source of controls (χ2 = 14.53, df = 1
and p < 0.001), but not the ethnicity (χ2 = 1.28, df = 1 and
p = 0.258).
Publication bias
We performed Begg’s funnel plot and Egger’s test to
assess the publication bias of literatures. As shown in
Figure 2, the shape of the funnel plots did not reveal any
evidence of obvious asymmetry. The results of Egger’s
test still did not suggest any evidence of publication bias
for 3435C > T polymorphism (p =0.085 for TT vs. CC,
p =0.273 for CT vs. CC, p = 0.102 for dominant model,
respectively and p = 0.176 for recessive model). There
are neither Publication bias for 1236C > T polymorphism










Figure 2 Begg’s funnel plots for publication bias test (3435C > T TT v
association. Log (OR), natural logarithm of OR. Horizontal line, means effectfor dominant model, respectively and p = 0.332 for
recessive model), nor for 2677G > T/A polymorphism
(p =0.716 for TT + TA + AA vs. GG and p = 0.656 for
recessive model, p =0.841 for GT + GA vs. GG, p = 0.971
for dominant model, respectively).
Discussion
ATP-binding cassette (ABC) is one of the largest families
of active importers and exporters that are located mainly
in tissues acting as a barrier or having an excretory func-
tion. Most of the ABC transporters play a role in cell
defense against environmental attacks generated by
xenobiotics and intraceullar metabolic waste. The
multidrug resistance 1 (MDR1/ABCB1) gene codes for
P-glycoprotein, a membrane-bound transporter. Various
cytokines, such as interleukin-1beta, benzo [a]pyrene
and chemokines involved in inflammation seem to be the
substrates of P-glycoprotein, which leading P-glycoprotein
to be a potential cause of inflammation-induced carcino-
genesis. MDR1 also seems to play a role in preventing
early apoptosis in tumor cells.
Significant MDR1 gene heterogeneity, namely multiple
mutations in the ABCB1/MDR1 gene has been demon-
strated in previous studies. Analysis of all 28 exons of
the ABCB1/MDR1 gene demonstrated at least 48 single-
nucleotide polymorphisms (SNPs) to date, including
promoter and the intron–exon region. The most fre-
quent SNP MDR1 2677G > T/A in exon 21 (RefSNP ID:
rs2032582), leads to amino acid exchange from Ala to
Ser or Thr. The silent mutation in exon 26 MDR1
3435C > T (RefSNP ID: rs1045642) is associated with
altered protein function. The third common polymorph-
ism of ABCB1/MDR1 gene is a silent mutation in exonudo 95% confidence limits
 of: logor
.4 .6
s. CC). Each point represents a separate study for the indicated
size.
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http://www.cancerci.com/content/13/1/4612 MDR1 1236C > T (RefSNP ID: rs1128503). These
three polymorphisms are closely related to linkage dis-
equilibrium (LD). It was suggested that SNP is
connected with susceptibility to many cancer types, such
as renal epithelial tumors and acute lymphoblastic
leukemia and CRC.
Our results showed that MDR1 3435C > T poly-
morphism is associated with cancer risk when all studies
were pooled together (TT versus CC: OR =1.286, 95%
CI =1.123–1.474; CT versus CC: OR = 1.126, 95% CI =
1.020–1.244; dominant model TT + CT versus CC: OR =
1.176, 95% CI = 1.068–1.295; recessive model TT versus
CT + CC: OR =1.191, 95% CI =1.065–1.333). In the strati-
fied analysis by cancer type, the results indicated that indi-
viduals with T-allele in 3435C > T had significantly higher
ALL risks (TT versus CC: OR =1.890, 95% CI =1.177–
3.037; TT + CT versus CC: OR = 1.240, 95% CI = 1.046–
1.470; recessive model TT versus CT + CC: OR = 1.829,
95% CI =1.095–3.054), otherwise no significant associ-
ation was found between higher CRC risks and T-allele in
3435C > T, neither was between breast cancer and T-allele
in 3435C > T. When stratified by ethnicity, significantly
elevated risks were observed among Caucasian popula-
tions(co-dominant model TT versus CC: OR =1.276,
95% CI =1.112–1.464; CT versus CC: OR = 1.172, 95%
CI = 1.047–1.313; dominant model TT + CT versus CC:
OR = 1.212, 95% CI = 1.083–1.357), whereas significantly
elevated risks were not observed among Asian populations
(co-dominant model TT versus CC: OR =1.314, 95%
CI =0.894–1.933). When restricting the analysis to the
source of controls, we found that HB genetic models had
higher risks (TT versus CC: OR =1.307, 95% CI =1.046–
1.632; dominant model: OR =1.170, 95% CI =1.009–
1.357), and association was detected in PB genetic models
also (TT versus CC: OR =1.294, 95% CI =1.079–1.552; CT
versus CC: OR = 1.150, 95% CI = 1.019–1.299; dominant
model TT + CT versus CC: OR = 1.459, 95% CI = 1.246–
1.709; recessive model TT versus CT + CC: OR =1.183,
95% CI =1.033–1.355).
Inconsistent results might be attributed to the different
roles MDR1 played in different cell types or tissues.
We’ve found the association between MDR1 3435C > T
polymorphism and ALL risk in subgroup analyses, as
well as subgroup based on HB and PB genetic models.
And in the stratified analysis by ethnicity, individuals
carrying the T-allele in 3435C > T were significantly as-
sociated with elevated cancer risk in Asian as well as
Caucasian populations compared with C-allele carriers.
We also found that T/A-allele frequency of 2677G > T/
A polymorphism was associated with higher risk of cancer
(2677G > T/A: TT + TA + AA vs. GG: OR =1.348, 95%
CI =1.031–1.762). In the subgroup analysis by ethnicity,
significantly elevated risks were observed among Asian
populations (co-dominant model TT + TA + AA vs.GG: OR =1.642, 95% CI =1.340–2.012), however no
significantly elevated risks were observed among Caucasian
populations. When stratified by the source of controls,
we couldn’t find association between HB genetic models
and higher cancer risks, but elevated risks could be associ-
ated with PB models (TT + TA + AA vs. GG: OR =1.641,
95% CI =1.018–2.646; GA + GT vs. GG: OR =1.164, 95%
CI =1.008–1.345; dominant model: OR = 1.284, 95%
CI =1.122–1.470).
The combined result based on all studies showed that
there was no statistically significant link between cancer risk
and 1236C > T (1236C > T: TT vs. CC: OR =1.325, 95%
CI =0.824–2.133; CT vs. CC: OR = 1.133, 95% CI =
0.817–1.573; dominant model: OR = 1.173, 95% CI =
0.825–1.688; recessive model: OR = 1.191, 95% CI =0.840–
1.690).
It should be considered that the apparent inconsist-
ency of these results may be caused by differences in dis-
ease prevalence, lifestyle, as well as possible limitations
due to the relatively small sample size. The current
knowledge of carcinogenesis indicates it is a process de-
veloped step by step, as well as influenced by multiple
factors that involve various genetic alterations and sev-
eral signaling pathways. Thus, it is unlikely that risk fac-
tors of cancer work in isolation from each other.
Besides, even the same polymorphisms may act distinct
roles in each cancer type, for different genetic back-
grounds may contribute to the cancer discrepancy. And
more importantly, the appearance determined by polymor-
phisms may largely depend on synthetically interaction
with each polymorphism or a particular environmental ex-
posure. Thus, it is possible that the effects of DNA repair
function on cancer risk may be modified by multiple gen-
etic polymorphisms. Also should we consider the chance
findings as another plausible reason for the inconsistency
of the results.
Although we have put considerable resources and
efforts into discovering the association between MDR1
polymorphism and cancer risk as possible as we can,
there still exists some limitations. First, when stratified
by the source of controls, our results indicated that stud-
ies using hospital-based controls rather than population-
based controls had a significantly increased risk. The
reason may be that the hospital-based studies have some
biases because such controls may contain certain other
diverse diseases which can cause different risks of devel-
oping into cancer of various organs and may not be so
representative as the general population. Therefore,
using proper and more representative cancer-free con-
trol subjects are crucial for reducing biases in such
case–control studies. Second, our results were based on
single-factor estimates without adjustment for other risk
factors such as age, smoking and drinking status, envir-
onmental factors and other variables, which might have
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publication bias might exist. Finally, the number of the
published studies was not sufficiently large for a com-
prehensive analysis, particularly for the 1236C > T poly-
morphism. Hence we had to give up subgroup analysis
for the polymorphism. For these limitations, our results
should be interpreted with caution.
Our meta-analysis also has several strengths. First, sta-
tistically, a systematic review of the association of MDR1
polymorphism between cancer risks is more powerful
than any single study. Second, the quality of eligible
studies included in current meta-analysis was satisfac-
tory and met our inclusion criterion. Third, we did not
detect sufficient publication bias indicating that the
whole results might be unbiased.
In conclusion, our meta-analysis suggests that the
MDR1 3435C > T and 2677G > T/A polymorphism may
contribute to genetic susceptibility of cancers. And the
results support that the minor T-allele of the MDR1
3435C > T polymorphism is associated with a higher
risk of acute lymphocytic leukemia, and significantly ele-
vated risks were observed among Asian and Caucasian
populations as well as HB and PB subgroups. And in the
2677G > T/A polymorphism, those who carry the T-
allele and A-allele were associated with higher cancer
risks among Asians and PB subgroup. However, it is ne-
cessary to conduct large sample studies using standard-
ized unbiased genotyping methods, homogeneous cancer
patients and well-matched controls. Moreover, further
studies estimating the effect of gene–gene and gene–en-
vironment interactions may eventually lead to our better,
comprehensive understanding of the association between
the MDR1 polymorphism and cancer risk.
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